Dr. Jan Skvarka, PhD's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 57,100 Common Stock done . Disclosure was reported to the exchange on June 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharma Inc | Dr. Jan Skvarka, M.B.A.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2026 | 57,100 | 264,254 | - | 0 | Common Stock | |
| Monte Rosa Therapeutics Inc | Dr. Jan Skvarka, M.B.A.,PhD | Director | 11 Jun 2026 | 25,800 | 25,800 | - | - | Stock Option (Right to Buy) | ||
| Zentalis Pharma Inc | Dr. Jan Skvarka, M.B.A.,PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 57,603 | 207,154 | - | 0 | Common Stock | |
| Monte Rosa Therapeutics Inc | Dr. Jan Skvarka, M.B.A.,PhD | Director | 13 Jun 2025 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | ||
| Zentalis Pharma Inc | Dr. Jan Skvarka, M.B.A.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 1.72 per share. | 31 Jan 2025 | 60,000 | 149,551 | - | 1.7 | 103,446 | Common Stock |
| Zentalis Pharma Inc | Dr. Jan Skvarka, PhD | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 41,581 | 89,551 | - | 0 | Common Stock | |
| Monte Rosa Therapeutics Inc | Dr. Jan Skvarka, PhD | Director | 12 Jun 2024 | 22,100 | 22,100 | - | - | Stock Option (Right to Buy) |